| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,050 | 6,600 | 13:51 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 20,000 | 83 | |||
| 16,000 | 32 | |||
| 13,500 | 100 | |||
| 10,500 | 100 | |||
| 9,500 | 178 | |||
| 8,550 | 450 | |||
| 8,000 | 41 | |||
| 6,500 | 752 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 752 | 6,200 | |||
| 700 | 4,740 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.452 | 1,222 | 1.775 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 28.10.2026 | 16:00:20 | 6,350 | 500 |
| Tagesumsatz Xetra | 0,000 0,00 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | 4basebio Plc - Result of Retail Offer | 416 | PR Newswire | 4basebio Plc - Result of Retail OfferPR NewswireLONDON, United Kingdom, October 21
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS... ► Artikel lesen | |
| 20.10. | 4basebio Plc - Posting of Circular and Notice of General Meeting | 348 | PR Newswire | 4basebio Plc - Posting of Circular and Notice of General MeetingPR NewswireLONDON, United Kingdom, October 20
20 October 2026
4basebio PLC
("4basebio" or the "Company")
Posting... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 15.10. | TRADING UPDATES: 4basebio fundraise; Geo Exploration secures grants | 4 | Alliance News | ||
| 15.10. | 4basebio Plc - Proposed Retail Offer | 575 | PR Newswire | 4basebio Plc - Proposed Retail OfferPR NewswireLONDON, United Kingdom, October 15
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS... ► Artikel lesen | |
| 15.10. | 4basebio Plc - Results of Capital Raise | 565 | PR Newswire | 4basebio Plc - Results of Capital RaisePR NewswireLONDON, United Kingdom, October 15
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 12:09 | Iovance Biotherapeutics Inc. - IOVA: weißer Rauch bei Lungenkrebs-Daten? | ratgeberGELD.at | Intraday Trade? Rekordumsatz in Q2 bei Iovance Biotherapeutics. Lifileucel-Therapie mit Mega-Marktpotenzial! Vorbörsliches Gap Up! Iovance Biotherapeutics (IOVA) - US4622601007 Rückblick Nach einer... ► Artikel lesen | |
| 11:10 | Moderna-Aktie: Kracht es am 6. November? | sharedeals.de | Moderna zählt 2026 mit mehr als 600% Kursgewinn zu den stärksten Aktien am Markt und hat sogar große KI-Konzerne deutlich übertroffen. Am 6. November könnten die Quartalszahlen neue Impulse liefern... ► Artikel lesen | |
| 12:10 | Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma | GlobeNewswire (Europe) | SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 12:03 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 12:10 | Biogen Inc.: Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026 | GlobeNewswire (Europe) | Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's diseaseLecanemab... ► Artikel lesen |